<!DOCTYPE html>
<html lang="en">

<head>
  <title>HTN | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/buttons.css" />

  
    <link rel="stylesheet" href="/peripheral_brain/css/diseases.css">
  


  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Condensed" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/site.webmanifest">
  <link rel="mask-icon" href="/peripheral_brain/favicons/safari-pinned-tab.svg" color="#465c8b">
  <link rel="shortcut icon" href="/peripheral_brain/favicons/favicon.ico">
  <meta name="apple-mobile-web-app-title" content="Peripheral Brain">
  <meta name="application-name" content="Peripheral Brain">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/peripheral_brain/favicons/browserconfig.xml">
  <meta name="theme-color" content="#cdcdcd">


  

</head>


<body class="body">
<header id="myHeader" class="myHeader">
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
    <a href="/peripheral_brain/home.html">Home</a>
    <a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a>
    <a href="/peripheral_brain/firstFive">TF5M</a>
    <a href="/peripheral_brain/lab_values">Lab Values</a>
    <a href="/peripheral_brain/formulas">Formulas</a>
    <a href="/peripheral_brain/calculators.html">Calculators</a>
    <a href="/peripheral_brain/search.html">Search</a>
    <a href="javascript:void(0);" class="icon" onclick="openMenu()">&#9776;</a>
  </nav>

  <script>
  function openMenu() {
      var x = document.getElementById("myHeader");
      if (x.className === "myHeader") {
          x.className += " responsive";
      } else {
          x.className = "myHeader";
      }
  }
  </script>
</header>


<h1 class="title">HTN</h1>

<div class="contents twoCol">
  <div class="toc col1">
    
      <ul>
  <li><a href="#dx">Dx<sup id="fnref:whelton2018"><a href="#fn:whelton2018" class="footnote">1</a></sup></a>
    <ul>
      <li><a href="#causes-of-secondary-htn">Causes of Secondary HTN</a></li>
      <li><a href="#misc-recommendations">Misc Recommendations</a></li>
    </ul>
  </li>
  <li><a href="#tx">Tx<sup id="fnref:whelton2018:1"><a href="#fn:whelton2018" class="footnote">1</a></sup></a></li>
  <li><a href="#htn-crisis">HTN Crisis<sup id="fnref:whelton2018:2"><a href="#fn:whelton2018" class="footnote">1</a></sup><sup>, </sup><sup id="fnref:benken2018"><a href="#fn:benken2018" class="footnote">2</a></sup></a>
    <ul>
      <li><a href="#dx-1">Dx</a></li>
      <li><a href="#tx-1">Tx</a></li>
    </ul>
  </li>
  <li><a href="#references">References</a></li>
</ul>

    
  </div>

  <div class="content col2">
    <h1 id="dx">Dx<sup id="fnref:whelton2018"><a href="#fn:whelton2018" class="footnote">1</a></sup></h1>

<table>
  <thead>
    <tr>
      <th>Category</th>
      <th>SBP</th>
      <th>DBP</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Normal</td>
      <td>&lt; 120</td>
      <td>&lt; 80</td>
    </tr>
    <tr>
      <td>Elevated</td>
      <td>120-129</td>
      <td>&lt; 80</td>
    </tr>
    <tr>
      <td>Stage 1</td>
      <td>130-139</td>
      <td>80-89</td>
    </tr>
    <tr>
      <td>Stage 2</td>
      <td>≥ 140</td>
      <td>≥ 90</td>
    </tr>
  </tbody>
</table>

<h2 id="causes-of-secondary-htn">Causes of Secondary HTN</h2>

<ul>
  <li>Renal disease</li>
  <li>Hyperaldosteronism</li>
  <li>OSA</li>
  <li>Drug / EtOH induced
    <ul>
      <li>Amphetamines</li>
      <li>NE acting antidepressants</li>
      <li>Caffeine</li>
      <li>Atypical antipsychotics</li>
      <li>Stimulant decongestants</li>
      <li>Immunosuppressants</li>
      <li>Hormonal contraceptives</li>
      <li>NSAIDs</li>
      <li>GCs</li>
      <li>MCs</li>
      <li>Angiogenesis inhibitors</li>
      <li>Tyrosine Kinase inhibitors</li>
    </ul>
  </li>
  <li>Pheochromocytoma</li>
  <li>Cushing’s</li>
  <li>Hyper / hypothyroidism</li>
  <li>Aortic coarctation</li>
  <li>Hyperparathyroidism</li>
  <li>Adrenal hyperplasia</li>
  <li>Acromegaly</li>
</ul>

<h2 id="misc-recommendations">Misc Recommendations</h2>

<ul>
  <li>Screen for primary aldosteronism in its with resistant HTN, especially those w/ hypokalemia, stroke at a young age, or FHx of early-onset HTN</li>
  <li></li>
</ul>

<h1 id="tx">Tx<sup id="fnref:whelton2018:1"><a href="#fn:whelton2018" class="footnote">1</a></sup></h1>

<ul>
  <li>General Treatment Algorithm
    <ul>
      <li>Stage 1ASCVD Risk &lt; 10%: Non-pharm and reassess in 3-6mo</li>
      <li>Otherwise, non-pharm and pharmacotherapy and reassess in 1mo</li>
    </ul>
  </li>
  <li>Target &lt; 130/80 for all pts
    <ul>
      <li>Consider starting 2 drugs if in Stage 2 or &gt; 20/10 above target</li>
      <li>Stroke pts w/ previously Dx HTN before stroke are the exception, target &lt; 140/90</li>
    </ul>
  </li>
  <li>ACEI / ARB Best first Choice
    <ul>
      <li>SIHD (also β-blockers)</li>
      <li>CKD (≥ Stage 3 or w/ significant albuminuria)</li>
    </ul>
  </li>
  <li>Use CCBs and Thiazides in AA pts d/t inherently low levels of RAAS activity</li>
  <li>DM
    <ul>
      <li>All 1st line agents now appropriate</li>
    </ul>
  </li>
</ul>

<p class="caption">Non-pharm Interventions and BP Impact</p>

<table>
  <thead>
    <tr>
      <th>Intervention</th>
      <th>Decrease</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Wt loss</td>
      <td>1 / kg</td>
    </tr>
    <tr>
      <td>Healthy diet</td>
      <td>11</td>
    </tr>
    <tr>
      <td>Na &lt; 1500mg QD</td>
      <td>5-6</td>
    </tr>
    <tr>
      <td>K 3500-5000mg QD</td>
      <td>4-5</td>
    </tr>
    <tr>
      <td>Exercise</td>
      <td>4-8</td>
    </tr>
    <tr>
      <td>Decreased EtOH</td>
      <td>4</td>
    </tr>
  </tbody>
</table>

<p class="caption">First-Line Drugs and Doses</p>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Usual Daily Dose (mg)</th>
      <th>Frequency</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="3">Thiazides</td>
    </tr>
    <tr>
      <td>Chlorthalidone</td>
      <td>12.5-25</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>HCTZ</td>
      <td>25-50</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Indapamide</td>
      <td>1.25-2.5</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Metolazone</td>
      <td>2.5-5</td>
      <td>QD</td>
    </tr>
    <tr>
      <td colspan="3">ACEIs</td>
    </tr>
    <tr>
      <td>Enalapril</td>
      <td>5-40</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>10-40</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Quinapril</td>
      <td>10-80</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td>Ramipril</td>
      <td>2.5-20</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td colspan="3">ARBs</td>
    </tr>
    <tr>
      <td>Candesartan</td>
      <td>8-32</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Irbesartan</td>
      <td>150-300</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>50-100</td>
      <td>QD or BID</td>
    </tr>
    <tr>
      <td>Valsartan</td>
      <td>80-320</td>
      <td>QD</td>
    </tr>
    <tr>
      <td colspan="3">DHP CCBs</td>
    </tr>
    <tr>
      <td>Amlodipine</td>
      <td>2.5-10</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Nicardipine SR</td>
      <td>60-120</td>
      <td>BID</td>
    </tr>
    <tr>
      <td>Nifedipine LA</td>
      <td>30-90</td>
      <td>QD</td>
    </tr>
    <tr>
      <td colspan="3">Non-DHP CCBs</td>
    </tr>
    <tr>
      <td>Diltiazem ER</td>
      <td>120-360</td>
      <td>QD</td>
    </tr>
    <tr>
      <td>Verapamil IR</td>
      <td>120-360</td>
      <td>TID</td>
    </tr>
    <tr>
      <td>Verapamil SR</td>
      <td>120-360</td>
      <td>QD or BID</td>
    </tr>
  </tbody>
</table>

<h1 id="htn-crisis">HTN Crisis<sup id="fnref:whelton2018:2"><a href="#fn:whelton2018" class="footnote">1</a></sup><sup>, </sup><sup id="fnref:benken2018"><a href="#fn:benken2018" class="footnote">2</a></sup></h1>

<h2 id="dx-1">Dx</h2>

<ul>
  <li>BP &gt; 180/120</li>
  <li>
    <p>Evidence of end-organ damage ⇒ emergency, otherwise ⇒ urgency</p>

    <ul>
      <li>ICH</li>
      <li>HTN encephalopathy</li>
      <li>Cerebral infarct</li>
      <li>Acute pulmonary edema</li>
      <li>Acute HF</li>
      <li>ACS</li>
      <li>AKI</li>
      <li>LFT elevation (most commonly w/ HELLP syndrome)</li>
      <li>Retinal hemorrhage</li>
      <li>Eclampsia</li>
      <li>Aortic dissection</li>
    </ul>
  </li>
</ul>

<h2 id="tx-1">Tx</h2>
<ul>
  <li>Urgency
    <ul>
      <li>Restart or intensify home PO regimine w/ close f/u</li>
    </ul>
  </li>
  <li>Emergency
    <ul>
      <li>IV antihypertensives</li>
      <li>Target 25% BP decrease in 1hr, then 160/110 in the following 2-6hrs, then normal BP w/i 24-48hrs</li>
      <li><strong>Pre-/eclampsia, aortic aneurism, stroke, and pheochromocytoma have special therapies</strong></li>
    </ul>
  </li>
  <li>Ischemic Stroke
    <ul>
      <li>Treat to 185/110 before thrombolysis and 180/105 after thrombolysis</li>
      <li>Treat if not thrombolysing and have evidence of end-organ damage or &gt; 220/120</li>
    </ul>
  </li>
</ul>

<p class="caption">IV Antihypertensives</p>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Initial Dose</th>
      <th>Max Dose</th>
      <th>Onset</th>
      <th>Duration</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="6">CCBs</td>
    </tr>
    <tr>
      <td>Nicardipine</td>
      <td>5 mg/hr<br />Increase 2.5 mg/hr Q5-10min</td>
      <td>15mg/hr</td>
      <td>5-10min</td>
      <td>2-6hr</td>
      <td>CI in advanced aortic stenosis</td>
    </tr>
    <tr>
      <td>Clevidipine</td>
      <td>1-6mg/hr<br />Titrate 1-2 mg/hr Q90s</td>
      <td>32mg/h<br />72hr use</td>
      <td>1-4min</td>
      <td>5-15min</td>
      <td>Low end of range in elderly</td>
    </tr>
    <tr>
      <td colspan="6">Vasodilators</td>
    </tr>
    <tr>
      <td>Nitroprusside</td>
      <td>0.25-0.5 mcg/kg/min<br />Titrate 0.1-0.2 mcg/kg/min Q5-10min</td>
      <td>10 mcg/kg/min</td>
      <td>Seconds</td>
      <td>1-2min</td>
      <td>Give thiosulfate to prevent CN poisoning if &gt; 30min or ≥ 4 mcg/kg/min</td>
    </tr>
    <tr>
      <td>NTG</td>
      <td>5 mcg/min<br />Titrate by 0.1-0.2 mcg/kg/min Q5min</td>
      <td>200 mcg/min</td>
      <td>2-5min</td>
      <td>5-10min</td>
      <td>Preferred in ACS or acute pulmonary edema<br />CI in volume dependent states (e.g. right-ventricular infarct)</td>
    </tr>
    <tr>
      <td>Hydralazine</td>
      <td>10mg slow IV infusion Q4-6hr<br />IM: 10mg Q30min</td>
      <td>20mg initial<br />IM: 40mg</td>
      <td>IV: 10min<br />IM: 20min</td>
      <td>IV: 1-4hr<br />IM: 2-6hr</td>
      <td>Highly unpredictable<br />10-30min to start, and lasts 4-6hr</td>
    </tr>
    <tr>
      <td colspan="6">β-Blockers</td>
    </tr>
    <tr>
      <td>Esmolol</td>
      <td>500-1000 mcg/kg over 1min then 50 mcg/kg/min infusion<br />Titrate 25 mcg/kg/min Q3-5min</td>
      <td>200 mcg/kg/min</td>
      <td>1-2min</td>
      <td>10-20min</td>
      <td>β<sub>1</sub> selective<br />Don’t use in HF, other β-blocker use, or existing bradycardia / heart block</td>
    </tr>
    <tr>
      <td>Labetalol</td>
      <td>0.3-1 mg/kg (20-80mg) Q5-10min<br />or<br />0.4-1 mg/kg/hr (0.5-10 mg/min)</td>
      <td>Titrate infusion by 1-2mg/min Q2hr</td>
      <td>2-5min (peak 5-15min)</td>
      <td>2-6hr (up to 18hr in some pts)</td>
      <td>Non-selective blockade<br />CI in reactive airway disease<br />Avoid in heart block / bradycardia / HF</td>
    </tr>
    <tr>
      <td>Metoprolol</td>
      <td>5-15mg Q5-15min</td>
      <td>&nbsp;</td>
      <td>5-20min</td>
      <td>2-6hr</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td colspan="6">α-Blockers</td>
    </tr>
    <tr>
      <td>Phentolamine</td>
      <td>5mg Q10min PRN</td>
      <td>&nbsp;</td>
      <td>Seconds</td>
      <td>15min</td>
      <td>Most useful in catecholamine excess (pheochromocytoma, MAOI interactions, cocaine / amphetamine overdose, etc)</td>
    </tr>
    <tr>
      <td colspan="6">D<sub>1</sub> Antagonist</td>
    </tr>
    <tr>
      <td>Fenoldopam</td>
      <td>0.1-0.3 mcg/kg/min</td>
      <td>Increase 0.05-0.1 mch/kh/min Q15min to target BP NTE 1.6 mcg/kg/min</td>
      <td>10-15min</td>
      <td>10-15min</td>
      <td>CI in pts w/ increase IOP or ICP or sulfite allergy</td>
    </tr>
    <tr>
      <td colspan="6">ACEI</td>
    </tr>
    <tr>
      <td>Enalaprilat</td>
      <td>1.25mg over 5min</td>
      <td>Increase 5mg Q6h PRN</td>
      <td>15-30min</td>
      <td>12-24hr</td>
      <td>CI in pregnancy, bilateral renal artery stenosis, acute MI<br />Slow onset (15min)<br />Unpredictable</td>
    </tr>
  </tbody>
</table>
<p class="caption">Preferred Agents in Specific Circumstances<sup id="fnref:whelton2018:3"><a href="#fn:whelton2018" class="footnote">1</a></sup></p>

<table>
  <thead>
    <tr>
      <th>Condition</th>
      <th>Preferred Drug</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Aortic Dissection</td>
      <td>Esmolol, labetolol</td>
      <td>Rapidly lower to SBP ≤ 120 w/i 20min<br />If needed, can add vasodilator, but must add rate-control first</td>
    </tr>
    <tr>
      <td>Acute Pulmonary Edema</td>
      <td>Clevidipine, NTG, nitropruside</td>
      <td>β-blockers CI</td>
    </tr>
    <tr>
      <td>ACS</td>
      <td>Esmolol, labetolol, nicardipine, NTG</td>
      <td>Watch for PDE inhibitors if giving nitrate based therapy</td>
    </tr>
    <tr>
      <td>Acute renal Failure</td>
      <td>Clevidipine, fenoldopam, nicardipine</td>
      <td> </td>
    </tr>
    <tr>
      <td>Pre-/Eclampsia</td>
      <td>Hydralazine, labetolol, nicardipine</td>
      <td>Lower rapidly</td>
    </tr>
    <tr>
      <td>Perioperative HTN</td>
      <td>Clevidipine, esmolol, nicardipine, NTG</td>
      <td> </td>
    </tr>
    <tr>
      <td>Sympathetic Excess (cocaine, amphetamines, pheochromocytoma, etc)</td>
      <td>Clevidipine, nicardipine, phenotolomine</td>
      <td> </td>
    </tr>
  </tbody>
</table>

<p class="caption">IV Antihypertensive Hemodynamic Effects</p>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Preload</th>
      <th>Afterload</th>
      <th>CO</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CCBs</td>
      <td> </td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Nicardipine</td>
      <td>↔</td>
      <td>↓</td>
      <td>↑</td>
    </tr>
    <tr>
      <td>Clevidipine</td>
      <td>↔</td>
      <td>↓</td>
      <td>↑</td>
    </tr>
    <tr>
      <td>Vasodilators</td>
      <td> </td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Nitroprusside</td>
      <td>↓</td>
      <td>↓↓</td>
      <td>↑</td>
    </tr>
    <tr>
      <td>NTG</td>
      <td>↓↓</td>
      <td>↓↔</td>
      <td>↔↑</td>
    </tr>
    <tr>
      <td>Hydralazine</td>
      <td>↔</td>
      <td>↓</td>
      <td>↑</td>
    </tr>
    <tr>
      <td>β-Blockers</td>
      <td> </td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Esmolol</td>
      <td>↔</td>
      <td>↔</td>
      <td>↓</td>
    </tr>
    <tr>
      <td>Labetolol</td>
      <td>↔</td>
      <td>↓</td>
      <td>↓</td>
    </tr>
    <tr>
      <td>Metoprolol</td>
      <td>↔</td>
      <td>↔</td>
      <td>↓</td>
    </tr>
    <tr>
      <td>α-Blockers</td>
      <td> </td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Phentolamine</td>
      <td>↔</td>
      <td>↓</td>
      <td>↑</td>
    </tr>
    <tr>
      <td>D<sub>1</sub> Antagonists</td>
      <td> </td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Fenoldopam</td>
      <td>↔↓</td>
      <td>↓</td>
      <td>↑</td>
    </tr>
    <tr>
      <td>ACEI</td>
      <td> </td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Enalaprilat</td>
      <td>↓</td>
      <td>↓</td>
      <td>↑</td>
    </tr>
  </tbody>
</table>

<h1 id="references">References</h1>

<!-- Cardiology -->

<!-- ACS -->

<!-- HTN -->

<!-- VTE -->

<!-- CHF -->

<!-- HLD -->

<!-- Critical Care -->

<!-- Hypotension Management -->

<!-- Stress Ulcer Prophylaxis -->

<!-- ID -->

<!-- Vancomycin Dosing -->

<!-- Aminoglycoside Dosing -->

<!-- Pulmononolgy -->

<!-- Textbooks -->

<!-- Pharmacology -->

<!-- Emergency Medicine -->

<!-- Websites -->

<!-- Drug Resources -->

<div class="footnotes">
  <ol>
    <li id="fn:whelton2018">
      <p>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <em>Journal of the American College of Cardiology</em>. 2018;71(19):e127-e248. doi:<a href="https://doi.org/10.1016/j.jacc.2017.11.006">10.1016/j.jacc.2017.11.006</a> <a href="#fnref:whelton2018" class="reversefootnote">&#8617;</a> <a href="#fnref:whelton2018:1" class="reversefootnote">&#8617;<sup>2</sup></a> <a href="#fnref:whelton2018:2" class="reversefootnote">&#8617;<sup>3</sup></a> <a href="#fnref:whelton2018:3" class="reversefootnote">&#8617;<sup>4</sup></a></p>
    </li>
    <li id="fn:benken2018">
      <p>Benken ST. ACCP Hypertensive Emergencies. 2018. Available at: https://www.accp.com/docs/bookstore/ccsap/ccsap2018b1_sample.pdf <a href="#fnref:benken2018" class="reversefootnote">&#8617;</a></p>
    </li>
  </ol>
</div>

  </div>

</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-12-26 <br>
  Last Updated: 2018-12-27</p>
</div>

<footer class="footer menus">
  <nav>
    <div class="footerLinks">
      <a href="/peripheral_brain/home.html">Home</a>
      <a href="/peripheral_brain/index.html">Disclaimer</a>
      <a href="/peripheral_brain/disease_list_old.html">Archived Diseases</a>
    </div>
  </nav>
</footer>


</body>
</html>
